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OBJECTIVE—Our previous studies suggest that the SNARE
protein synaptosomal-associated protein of 23 kDa (SNAP23) is
involved in the link between increased lipid levels and insulin
resistance in cardiomyocytes. The objective was to determine
whether SNAP23 may also be involved in the known association
between lipid accumulation in skeletal muscle and insulin resis-
tance/type 2 diabetes in humans, as well as to identify a potential
regulator of SNAP23.
RESEARCH DESIGN AND METHODS—We analyzed skeletal
muscle biopsies from patients with type 2 diabetes and healthy,
insulin-sensitive control subjects for expression (mRNA and
protein) and intracellular localization (subcellular fractionation
and immunohistochemistry) of SNAP23, and for expression of
proteins known to interact with SNARE proteins. Insulin resis-
tance was determined by a euglycemic hyperinsulinemic clamp.
Potential mechanisms for regulation of SNAP23 were also inves-
tigated in the skeletal muscle cell line L6.
RESULTS—We showed increased SNAP23 levels in skeletal
muscle from patients with type 2 diabetes compared with that
from lean control subjects. Moreover, SNAP23 was redistributed
from the plasma membrane to the microsomal/cytosolic com-
partment in the patients with the type 2 diabetes. Expression of
the SNARE-interacting protein Munc18c was higher in skeletal
muscle from patients with type 2 diabetes. Studies in L6 cells
showed that Munc18c promoted the expression of SNAP23.
CONCLUSIONS—We have translated our previous in vitro
results into humans by showing that there is a change in the
distribution of SNAP23 to the interior of the cell in skeletal
muscle from patients with type 2 diabetes. We also showed that
Munc18c is a potential regulator of SNAP23. Diabetes 59:
1870–1878, 2010
I
nsulin resistance plays a major role in the develop-
ment of type 2 diabetes and is highly related to the
accumulation of triglycerides in skeletal muscle
(1,2). Triglycerides are stored in the cell in cytosolic
lipid droplets, which consist of a core of neutral lipids
surrounded by a monolayer of amphipathic lipids (3,4). It
is now recognized that lipid droplets are dynamic or-
ganelles with a complex surface that contains a number of
different proteins, including the structural PAT proteins
(5), lipid metabolic enzymes, and proteins involved in
processing and sorting of the droplets (6,7).
Lipid droplets are formed as primordial droplets and
increase in size by a fusion process that requires the
SNARE proteins synaptosomal-associated protein of 23
kDa (SNAP23), syntaxin-5, and vesicle-associated mem-
brane protein four (VAMP4) (8). SNAP23 is also required
for the insulin-stimulated translocation of GLUT4 to the
plasma membrane (9,10), and we previously demonstrated
that SNAP23 may play a role in the development of insulin
resistance (8). Speciﬁcally, we showed that accumulation
of lipid droplets in cardiomyocytes after fatty acid treat-
ment results in a redistribution of SNAP23 to the interior
of the cell, which coincides with the development of
cellular insulin resistance (8). However, this treatment
does not affect the total amount of SNAP23 (8). We also
showed that the fatty acid–induced increase in SNAP23 in
the interior of cardiomyocytes is at least partly explained
by increased levels of SNAP23 on lipid droplets (8).
However, the major amount of immunoreactive SNAP23 is
spread diffusely in the interior of the cell (8), and the
mechanism behind the redistribution has not been
clariﬁed.
Here, we tested if our in vitro observations in fatty
acid–treated cardiomyocytes (8) could be extrapolated to
the situation in vivo by comparing skeletal muscle biopsies
from patients with type 2 diabetes and matched lean and
obese control subjects. We showed that skeletal muscle
from patients with type 2 diabetes (and thus insulin
resistance) had increased lipid accumulation and redistri-
bution of SNAP23 to the microsomal/cytosolic fraction,
observations that were comparable with our ﬁndings in
fatty acid–treated cardiomyocytes (8). However, contrary
to the observation in cardiomyocytes, there was an in-
crease in total SNAP23 protein in the skeletal muscle
biopsies from patients with type 2 diabetes. We also found
that the SNARE-regulating protein Munc18c was increased
in skeletal muscle biopsies from patients with type 2
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RESEARCH DESIGN AND METHODS
Details of reagents, Western blot and RT-PCR analyses, quantiﬁcation of lipid
droplets, human skeletal myotubes, time-lapse studies, the skeletal muscle
cell line L6 G4m, and coprecipitation studies are available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1503/
DC1.
The main study population consisted of eight healthy, lean subjects and
eight obese, nondiabetic subjects carefully matched to eight obese patients
with type 2 diabetes. These subjects were recruited by the Diabetes Research
Centre at Odense University Hospital, Denmark. In addition, six monozygotic
twin pairs discordant for type 2 diabetes were recruited by the Diabetes
Research Centre at Odense University Hospital, Denmark, and ﬁve monozy-
gotic twin pairs discordant for type 2 diabetes were recruited from the
Swedish twin register. See online appendix for medication details and eligibility
criteria.
The subjects underwent a 4-h euglycemic hyperinsulinemic clamp and
routine analysis, and muscle biopsies were taken from the subjects before and
after the clamp as described (11). See online appendix for further details.
Subcellular fractionation. Muscle biopsy sample (50 mg) was homogenized
in 300 l of 10 mmol/l NaHCO3, pH 7.5, with 5 mmol/l NaN3, 100 mol/l
phenylmethylsulfonylﬂuoride, and the Complete Mini EDTA-free Protease
Inhibitor Cocktail (Roche Diagnostics AB) using the Polytron 1300D (Kine-
matica AG) homogenizer at speed 20 for 30 s. Homogenates were then
centrifuged for 1 min at 500g and 4°C, and the supernatants were transferred
to new tubes and recentrifuged for 10 min at 20,000g and 4°C. The pellet and
the supernatant were recovered and dissolved in SDS-gel electrophoresis
sample buffer.
To assess the recovery of cytosol, microsomes, and plasma membrane
during the procedure, we followed the recovery of marker enzymes present in
the homogenate of the skeletal muscle biopsies. The recovery of these marker
enzymes in the supernatant after the 500g centrifugation was as follows:
GAPDH, 60%; -tubulin, 63%; GRP78, 53%; Golgi protein 58k, 66%; and Na/K
ATPase, 58%; the recovery of SNAP23 was 75% (all results are the mean of two
experiments). The recovery of the marker enzymes present in the 500g
supernatant after the subsequent 20,000g centrifugation was as follows:
GAPDH, 97%; -tubulin, 100%; GRP78, 68%; Golgi protein 58k, 100%; and Na/K
ATPase, 54%; the recovery of SNAP23 was 59% (all results are the mean of two
experiments).
These results indicate a good recovery of the cytosol and microsomes
present in the supernatant of the skeletal muscle homogenate obtained after
the 20,000g centrifugation. Thus, we conclude that the cytosol and micro-
somes recovered in this subcellular fraction are representative of the cytosol
and microsomes present in the skeletal muscle biopsy sample.
The distribution of marker proteins between the supernatant (microsomes/
cytosol) and the pellet (containing the markers for plasma membrane and
t-tubules) obtained after the 20,000g centrifugation is shown in supplementary
Fig. 1 (available in an online appendix). The supernatant was highly enriched
in markers for microsomes and cytosol, while only traces of plasma mem-
brane and t-tubules were present in this fraction. We therefore conclude that
we isolated a microsomal/cytosolic fraction that was not contaminated to any
signiﬁcant degree with plasma membranes or t-tubules. The pellet was highly
enriched in markers for plasma membranes and t-tubules and was only
marginally contaminated by markers for cytosol and microsomes. However,
this fraction also contained most of the cellular organelles, and as indicated
above, the recovery of the plasma membrane markers was lower than the
recovery of the microsomal/cytosolic markers. These circumstances should
be taken into account when evaluating results about SNAP23 in the plasma
membrane.
Statistics. Comparisons of mean values from multiple groups were made
using one-way ANOVA and Tukey post hoc testing. ANOVA and Dunnett post
hoc testing was used to compare different groups with a control group.
Comparison between two groups was carried out by t test. Correlation tests
were performed using Pearson two-tailed correlation test. A P value of 0.05
was considered signiﬁcant. Presented P values are noncorrected.
RESULTS
Subject characteristics. Clinical data for patients with
type 2 diabetes and lean and obese control subjects are
shown in Table 1. The patients with type 2 diabetes had
signiﬁcantly lower insulin sensitivity compared with the
control subjects. This was supported by a lower phosphor-
ylation of AKT (Protein Kinase B) in the skeletal muscle
biopsies taken at the end of the euglycemic hyperinsuline-
mic clamp from patients with type 2 diabetes (Fig. 1A and
B; supplementary Fig. 2A and B [available in an online
appendix]). In addition, plasma HDL levels were lower and
plasma triglyceride levels were higher in the patients with
type 2 diabetes. We also showed that the accumulation of
neutral lipids (measured as the total area of Oil Red
O-stained lipid droplets) was greater in skeletal muscle
biopsy samples from patients with type 2 diabetes com-
pared with both lean and obese control subjects (Fig. 1C).
However, the extent of lipid droplet accumulation was
small even in the biopsy samples from patients with type 2
diabetes (Fig. 1C). There were no differences in any of
these variables between the control groups (Table 1; Fig.
1A and C).
Total SNAP23 protein levels in skeletal muscle are
increased in patients with type 2 diabetes. The total
SNAP23 mRNA levels were similar in skeletal muscle from
lean and obese control subjects and patients with type 2
diabetes (Fig. 2A). However, the total SNAP23 protein
levels were higher in skeletal muscle from patients with
type 2 diabetes than from the lean control subjects (Fig.
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FIG. 1. Decreased insulin-dependent AKT phosphorylation and in-
creased accumulation of neutral lipids in skeletal muscle biopsy sam-
ples from patients with type 2 diabetes. A: Phosphorylated AKT levels
(normalized to -tubulin) and B: representative immunoblots in skel-
etal muscle taken before (B) and after (A) a euglycemic hyperinsuline-
mic clamp from lean (LC) and obese (OC) control subjects and from
patients with type 2 diabetes (T2D). GAPDH has been used as loading
control. C: The total area of Oil Red O-stained lipid droplets in skeletal
muscle taken before a euglycemic hyperinsulinemic clamp from lean
and obese control subjects and from patients with type 2 diabetes. Data
are mean  SEM (n  8 for each group).
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cant negative correlation between total SNAP23 protein
levels in skeletal muscle and insulin sensitivity (deter-
mined as glucose infusion rate after the euglycemic hyper-
insulinemic clamp) when the results from the three groups
were combined (Fig. 3C). However, although there were
negative correlations between total SNAP23 levels in
skeletal muscle and insulin sensitivity in the individual
groups (lean control subjects, r  0.54, P  0.17; obese
control subjects, r  0.69, P  0.06; patients with type 2
diabetes, r  0.33, P  0.43), none of these individual
correlations were statistically signiﬁcant.
Is SNAP23 expression affected by environmental or
genetic inﬂuences? We addressed the role of genetic or
environmental inﬂuences on SNAP23 expression by inves-
tigating skeletal muscle from six pairs of monozygotic
Danish twins and ﬁve pairs of monozygotic Swedish twins
discordant for type 2 diabetes (see Table 1 for clinical
characteristics). For the Danish group, SNAP23 mRNA
levels in skeletal muscle did not differ between the twins
with type 2 diabetes and those without (Table 2). How-
ever, for the Swedish group, SNAP23 mRNA levels were
signiﬁcantly lower in skeletal muscle from the twins with
type 2 diabetes, and this difference remained when the
groups were combined (Table 2). By contrast, we did not
observe any differences in SNAP23 protein expression
between the twins with type 2 diabetes and those without
in either the Danish or Swedish group, or in the combined
group (Table 2).
To further address the role of environmental factors, we
incubated human myotubes (derived from satellite cells
from a metabolically healthy person) with high levels of
glucose, fatty acids, or insulin or combinations of these to
simulate the conditions present in type 2 diabetes. Fatty
acids and insulin combined signiﬁcantly decreased
SNAP23 mRNA levels (supplementary Fig. 3A). None of
these treatments affected the SNAP23 protein levels (sup-
plementary Fig. 3B).
SNAP23 levels in the microsomes/cytosol of skeletal
muscle are higher in patients with type 2 diabetes. We
have previously shown that oleic acid induces the redis-
tribution of SNAP23 and promotes insulin resistance in
HL1 cardiomyocytes in vitro (8). To determine whether
these ﬁndings translate to an in vivo situation, we investi-
gated if the localization of SNAP23 in skeletal muscle cells
differed between patients with type 2 diabetes (i.e., with
insulin resistance and increased levels of neutral lipids in
their skeletal muscle) and lean control subjects (i.e.,
without insulin resistance and with low levels of neutral
lipids in the skeletal muscle). The patients and control
subjects used in this study were randomly selected from
the main study population.
Subcellular fractionation of the skeletal muscle biopsy
samples showed that SNAP23 levels were higher in the
microsomal/cytosol fraction of skeletal muscle isolated
from patients with type 2 diabetes compared with that
from lean control subjects (Fig. 3A and B), and these levels
were similar in biopsy samples taken before or after the
euglycemic hyperinsulinemic clamp (data not shown).
SNAP23 levels were decreased in the plasma membrane/
t-tubule–containing fraction of skeletal muscle isolated
from patients with type 2 diabetes (Fig. 3C and D), but it is
important to note that this fraction also contains cellular
organelles. We also showed a clear separation between the
insulin-stimulated glucose infusion rates measured in the
patients with type 2 diabetes (range 40–220 mg/m
2/min;
n  3) and the rates measured in the lean control subjects
(range 300–400 mg/m
2/min; n  3), which suggests that
SNAP23 distribution is related to insulin sensitivity. To-
gether with our earlier in vitro results (8), these data
indicate that the diversion of SNAP23 to the interior of the
skeletal muscle cell may be important for the induction of
insulin resistance/type 2 diabetes.
To further investigate the localization of SNAP23, we
also used immunohistochemistry and confocal micros-
copy to analyze skeletal muscle from patients with type 2
TABLE 1
Clinical and metabolic characteristics of main study population and the two groups of monozygotic twin pairs discordant for type 2
diabetes
Main study population
Danish monozygotic
twin pairs discordant
for type 2 diabetes
Swedish monozygotic
twin pairs discordant
for type 2 diabetes
LC OC T2D Controls T2D Controls T2D
Men/Women 3/5 4/4 5/3 2/4 2/4 3/2 3/2
Age (years) 54.0  1.7 55.2  1.5 56.0  1.2 62  26 2  26 2  36 2  3
BMI (kg/m
2) 22.5  0.5 30.9  0.9
a 29.9  1.5
a 27.8  1.0 29.3  1.3 27.1  1.2 29.9  2.3
Fasting plasma glucose (mmol/l) 5.7  0.2 5.9  0.2 8.9  0.6
a,c 6.5  0.3 10.3  0.8
e 5.7  0.3 7.7  0.6
f
Fasting serum insulin (pmol/l) 32  63 4  49 1  20
b,d 83  21 91  19 30  3 148  87
HbA1c (%) 5.4  0.1 5.4  0.1 6.9  0.4 5.9  0.2 7.1  0.4** 4.7  0.1 5.9  0.4
g
Total cholesterol (mmol/l) 5.6  0.3 5.1  0.4 4.6  0.3 5.6  0.3 5.5  0.5 5.6  0.2 5.0  0.4
LDL (mmol/l) 3.6  0.2 3.3  0.3 3.1  0.2 3.5  0.3 3.1  0.4 3.3  0.3 2.9  0.2
HDL (mmol/l) 1.7  0.1 1.5  0.1 1.1  0.1
b,d 1.5  0.2 1.3  0.1 1.5  0.2 1.3  0.2
Plasma triglycerides (mmol/l) 0.9  0.1 1.0  0.2 1.6  0.2
b,d 1.8  0.7 2.5  0.6 1.1  0.2 1.5  0.4
Clamp plasma glucose (mmol/l) 5.4  0.1 5.4  0.2 5.4  0.2 5.4  0.2 5.4  0.1 5.5  0.1 5.7  0.12
Clamp serum insulin (pmol/l) 425  21 388  16 432  17 501  39* 431  16 667  19 896  264
Glucose infusion rate (mg/m
2/min) 312  22 287  22 129  28
a,c 217  34 133  19 396  31 250  113
Data are mean  SE (one-way ANOVA and Tukey post-hoc testing) for the main study population.
aP  0.001 and
bP  0.01 vs. lean control
subjects;
cP  0.001 and
dP  0.05 vs. obese control subjects. Data are mean  SE (Student t test for paired comparisons) for the monozygotic
twin pairs discordant for type 2 diabetes.
eP  0.012;
fP  0.043;
gP  0.048 vs. control. *One nondiabetic twin had fasting serum insulin of
162 pmol/l, which increased to 628 pmol/l during the clamp. However, the insulin-stimulated glucose infusion rate was very low (64
mg/m
2/min). The mean clamp serum insulin levels in the other ﬁve nondiabetic twins were 397  37 pmol/l. **P  0.06 vs. control. LC, lean
control, OC, obese control; T2D, type 2 diabetes.
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SNAP23 was mostly diffusely spread in the cytosol of
skeletal muscle cells from both groups, but higher levels of
immunoreactive SNAP23 were present in the plasma mem-
brane from the lean control subjects.
To clarify the nature of this cytosolic localization, we
microinjected a plasmid coding for SNAP23-CFP into
human myoblasts and followed SNAP23-CFP over time
using confocal microscopy (Fig. 5 and supplementary
Movie 1, available in online appendix 2). For comparison,
we also followed the membrane-spanning protein syn-
taxin-4, which is transferred to the plasma membrane
through the secretory pathway (supplementary Fig. 4 and
supplementary Movie 2, available in online appendix 3).
Expression of SNAP23-CFP was observed 130 min after
the injection. It appeared diffusely spread in the major part
of the cytosol, compatible with synthesis and accumula-
tion in the cytosol. Some ﬂuorescence was also localized
to organelle structures, most likely the Golgi apparatus.
The protein had reached the plasma membrane after
130–160 min. These results suggest that SNAP23 is syn-
thesized in the cytosol and sorted from this compartment
to the plasma membrane.
Munc18c levels are increased in skeletal muscle from
patients with type 2 diabetes, and Munc18c is a
candidate for the regulation of SNAP23 expression.
We also investigated the expression of proteins known to
interact with SNARE proteins or participate in the forma-
tion of lipid droplets: SNAPAP, a protein known to interact
with SNAP23 (12); Synip (13,14) and Munc18c (15), pro-
teins that interact with the SNARE complex involved in
GLUT4 translocation; ADRP, TIP47, and LSDP5, lipid
droplet–associated proteins (5); and PLD1 and ERK2,
enzymes important for the assembly of lipid droplets (16).
Of all the proteins investigated, the only signiﬁcant
change in mRNA expression was noted for Munc18c (Fig.
6A). Skeletal muscle from patients with type 2 diabetes
had higher levels of Munc18c mRNA compared with
biopsy samples from both lean and obese control subjects
(Fig. 6A) and higher levels of Munc18c protein compared
with that from lean control subjects (Fig. 6B; supplemen-
tary Fig. 2B and D). The levels of Munc18c protein were
slightly lower after the clamp (0.86  0.01 fold of levels
before the clamp; n  4; P  0.0002). No changes in
Munc18c mRNA expression were observed in adipose
tissue biopsy samples from patients with type 2 diabetes
compared with those from lean and obese control subjects
(data not shown).
Is Munc18c expression affected by environmental or
genetic inﬂuences? To determine whether an increased
ﬂow of lipids to skeletal muscle could affect Munc18c
expression, we incubated human myotubes with oleic acid
and observed increases in both mRNA and protein levels
of Munc18c (supplementary Fig. 5A and B). These results
indicate that Munc18c expression may be promoted by
environmental inﬂuences that result in increased levels of
fatty acids, but they do not rule out the importance of
genetic inﬂuences.
We addressed the role of genetic inﬂuences on Munc18c
expression by investigating skeletal muscle from the
monozygotic twins discordant for type 2 diabetes de-
scribed above. For the Danish group, neither the mRNA
nor protein levels of Munc18c were different in skeletal
muscle from the twins with type 2 diabetes compared with
that from the nondiabetic twins (Table 2). For the Swedish
group, Munc18c mRNA levels were signiﬁcantly lower in
skeletal muscle from the twins with type 2 diabetes, but
there were no differences in the Munc18c protein levels
(Table 2). Combining the results from the two groups
showed that neither the mRNA nor protein levels of
Munc18c were signiﬁcantly different between the twins
with type 2 diabetes and the nondiabetic twins (Table 2),
indicating that there may be a genetic background at least
for the increased expression of Munc18c protein in skele-
tal muscle from patients with type 2 diabetes.
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FIG. 2. Total skeletal muscle SNAP23 protein levels are higher in
patients with type 2 diabetes and correlate with markers of insulin
resistance. A: SNAP23 mRNA levels (normalized to actin mRNA) in
skeletal muscle from lean and obese control subjects and patients with
type 2 diabetes. B: SNAP23 protein levels (normalized to -tubulin) in
skeletal muscle from lean and obese control subjects and patients with
type 2 diabetes. The SNAP23 protein level in skeletal muscle from
healthy lean control subjects was 36.8  0.6 ng/mg solubilized muscle
protein (see supplementary Fig. 8, available in an online appendix).
Data are mean  SEM (n  8 per group). C: SNAP23 protein levels
(normalized to -tubulin) in skeletal muscle taken before the euglyce-
mic hyperinsulinemic clamp correlated negatively with glucose infu-
sion rates measured at the end of the clamp. Lean control subjects, F;
obese control subjects, E; patients with type 2 diabetes, Œ.
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expression. Overexpression of Munc18c in L6 G4m cells
promoted increased expression of total SNAP23 protein
(supplementary Fig. 6A). Although we also observed an
increase in the amount of SNAP23 in the microsomal/
cytosolic fraction (supplementary Fig. 6B), this increase
was not signiﬁcant when expressed as a percentage of the
total SNAP23 pool in the cell (data not shown). Transfec-
tion of human myotubes with Munc18c siRNA signiﬁcantly
reduced the Munc18c and SNAP23 protein levels (supple-
mentary Fig. 6C and D) but did not affect the distribution
of SNAP23 in the cell (data not shown).
Because these results indicated that Munc18c may pro-
mote the expression of SNAP23, we tested the possibility
that Munc18c increases SNAP23 expression by forming a
complex with SNAP23. We showed that Munc18c copre-
cipitated with syntaxin-4 in L6 G4m cells and that SNAP23
seemed to be completely excluded from the complex
between Munc18c and syntaxin-4 (supplementary Fig. 6E).
DISCUSSION
Our previous in vitro studies in cardiomyocytes demon-
strated that SNAP23 could have an important role in the
development of insulin resistance (8). Here, we investi-
gated the expression and localization of SNAP23 in vivo in
skeletal muscle biopsy samples from patients with type 2
diabetes and control subjects.
We ﬁrst showed that the patients with type 2 diabetes
(and thus insulin resistance) had increased accumulation
of lipid droplets in their skeletal muscle, in agreement with
earlier results (1,17,18). There was very little lipid accu-
mulation in biopsy samples from both lean healthy and
obese nondiabetic control subjects, demonstrating that
obese people do not necessarily store fat in their skeletal
muscles. Furthermore, we did not observe any major
difference in variables linked to insulin resistance between
these two control groups, consistent with the known
overlap in insulin sensitivity between lean control subjects
and obese nondiabetic subjects (19).
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FIG. 3. SNAP23 protein levels in the microsomal/cytosolic fraction of skeletal muscle are higher in patients with type 2 diabetes. A: SNAP23
protein levels (normalized to -tubulin) and B: corresponding immunoblots in the microsomal/cytosolic fraction of skeletal muscle from lean
control subjects and patients with type 2 diabetes. C: SNAP23 protein levels (normalized to Na/K ATPase) and D: corresponding immunoblots in
the plasma membrane/t-tubule fraction of skeletal muscle from lean control subjects and patients with type 2 diabetes. Data are mean  SEM (n 
3 per group). A high-quality digital representation of this ﬁgure is available in the online issue.
TABLE 2
SNAP23 and Munc18c expression in skeletal muscle from Danish and Swedish monozygotic twin pairs discordant for type 2 diabetes
Danish twins Swedish twins Combined
SNAP23 mRNA 82  14 (n  5; ns) 62  11 (n  4; P  0.01) 73  9( n  9; P  0.02)
SNAP23 protein 97  7( n  6; ns) 102  22 (n  5; ns) 98  12 (n  11; ns)
Munc18c mRNA 94  16 (n  5; ns) 60  11 (n  5; P  0.02) 78  11 (n  10; ns)
Munc18c protein 149  37 (n  6; ns) 72  19 (n  5; ns) 122  24 (n  11; ns)
Data are presented as level in the twin with diabetes expressed as % of the level in the nondiabetic twin (mean SE).
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mRNA levels in skeletal muscle biopsy samples from
patients with type 2 diabetes and the two control groups.
This result contrasts with a recent study showing a statis-
tically signiﬁcant decrease in SNAP23 mRNA levels in
skeletal muscle from insulin-resistant women compared
with that from insulin-sensitive women (20). However,
when we compared monozygotic twins discordant for type
2 diabetes, we found a similar decrease in SNAP23 mRNA
levels in the twins with type 2 diabetes compared with the
nondiabetic twins in the Swedish cohort but not in the
Danish cohort. Thus, there may be population variations in
the expression of SNAP23 mRNA.
In contrast to mRNA, SNAP23 protein levels were higher
in skeletal muscle from patients with type 2 diabetes
compared with lean control subjects and did not differ
between the monozygotic twins discordant for type 2
diabetes in either the Swedish cohort or the Danish
cohort. This lack of reﬂection between SNAP23 mRNA and
protein expression argues for a posttranscriptional regu-
lation of SNAP23 expression.
The decrease in SNAP23 mRNA levels in Swedish twins
with type 2 diabetes (which remained when the two
cohorts of twins were combined) suggested that SNAP23
mRNA levels may depend on environmental factors,
whereas the lack of difference in SNAP23 protein levels
between the twins indicated a genetic inﬂuence on protein
expression. These ﬁndings were supported by our obser-
vation of decreased SNAP23 mRNA levels and no effect on
protein levels in human myotubes incubated under condi-
tions that simulate the situation in type 2 diabetes.
We have previously demonstrated that oleic acid pro-
motes insulin resistance, increases the storage of triglyc-
erides in lipid droplets, and induces the redistribution of
Negative control 
Lean controls
Type 2 diabetes
FIG. 4. Immunoreactive SNAP23 levels are higher in the plasma membrane of skeletal muscle from lean control subjects than from patients with
type 2 diabetes. Immunohistochemistry of SNAP23 in skeletal muscle from one lean control subject and one patient with type 2 diabetes. In the
negative control, nonimmune-IgG was used instead of anti-SNAP23. Arrowheads indicate the plasma membrane. The micrographs show
representative regions of longitudinal cuts of the skeletal muscle cells at different distances from their center. Bar, 10 m. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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cell in cardiomyocytes (8). A major aim of the present
study was to determine whether SNAP23 also redistributes
in vivo in patients with insulin resistance/type 2 diabetes.
By comparing patients with type 2 diabetes (i.e., patients
with insulin resistance and increased levels of neutral
lipids in their skeletal muscle) with lean control subjects
(subjects without insulin resistance and with low levels of
neutral lipids in the skeletal muscle), we obtained an in
vivo situation that resembled the earlier in vitro experi-
ments (8). It should be noted, however, that we cannot
separate insulin resistance from type 2 diabetes in this
study as we did not include a control group with insulin
resistance but without type 2 diabetes.
In agreement with the fatty acid–induced redistribution
of SNAP23 in HL-1 cardiomyocytes (8), subcellular frac-
tionation studies showed that SNAP23 was present at
higher levels in the microsomal/cytosolic fraction (i.e.,
interior of the cell) of skeletal muscle from patients with
type 2 diabetes compared with that from lean control
subjects. Immunohistochemistry and confocal microscopy
conﬁrmed that plasma membrane levels of SNAP23 were
lower in skeletal muscle from patients with type 2 diabe-
tes, while the majority of the protein was present in a
diffuse intracellular pattern compatible with a cytosolic
localization.
The cytosolic localization of SNAP23 was supported by
time-lapse studies in human myoblasts derived from sat-
ellite cells, which showed that SNAP23 was synthesized in
the cytosol and, although it reached the plasma mem-
brane, a substantial amount of the total pool remained in
the cytosol. These studies explain the cytosolic appear-
ance of SNAP23 in skeletal muscle from both the patients
with type 2 diabetes and the control subjects, and are
consistent with SNAP23 lacking signal and membrane-
spanning sequences; SNAP23 would thus not be cotrans-
lationally targeted to membranes or integrated into these
structures in other ways but would associate with mem-
branes by a process that is highly dependent on covalent
acylation (21).
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FIG. 5. SNAP23 is synthesized in the cytosol and moves from this compartment to the plasma membrane. Human myoblasts (derived from satellite
cells from skeletal muscle biopsy samples from a metabolically healthy person) were microinjected with a plasmid for SNAP23-CFP. SNAP23-CFP
was followed by confocal microscopy at the indicated times after microinjection. Bar, 10 m. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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hypothesis that SNAP23 redistribution plays an important
role in the development of insulin resistance and/or type 2
diabetes (8). Moreover, they suggest that the sorting of
SNAP23 from the biosynthesis pool in the cytosol to the
plasma membrane may be impaired in skeletal muscle
from patients with type 2 diabetes. Thus, an important
future task is to elucidate the intracellular processes
involved in sorting of SNAP23 between the interior of the
cell and the plasma membrane and to clarify how these
processes are changed in patients with type 2 diabetes. It
is also possible that the increased SNAP23 protein expres-
sion observed in skeletal muscle from patients with type 2
diabetes represents an attempt to overcome the insulin
resistance. Unfortunately, we could not test this possibility
as we did not induce a substantial and stable insulin
resistance in skeletal muscle cells by fatty acid treatment
(supplementary Fig. 7).
We also investigated the expression of proteins that
could potentially interact with SNAP23 in skeletal muscle
biopsy samples from patients with type 2 diabetes and the
lean and obese control subjects. Of the candidates inves-
tigated, only Munc18c expression differed between pa-
tients with type 2 diabetes and the control subjects, with
increased expression in skeletal muscle from patients with
type 2 diabetes. In agreement with an earlier study (22),
there were no differences in skeletal muscle Munc18c
levels between the lean and obese control subjects.
Munc18c binds to syntaxin-4/SNAP23/VAMP2, the
SNARE system of importance for fusion of GLUT4 vesicles
with the plasma membrane (15). The precise role of
Munc18c is not clear, as in some studies it has been shown
to inhibit GLUT4 translocation (23–27) and in others it has
been shown to promote GLUT4 translocation (28–30).
However, studies in transgenic mice demonstrated that
induction of Munc18c expression promotes insulin resis-
tance (31). Our results in humans support the view that
Munc18c plays a role in the development of insulin resis-
tance/type 2 diabetes. We did not observe any increase in
the expression of Munc18c in adipose tissue biopsy sam-
ples from patients with type 2 diabetes, indicating that the
potential role of Munc18c in the development of type 2
diabetes may be conﬁned to skeletal muscle.
We showed that Munc18c expression increased in human
myotubes incubated with oleic acid. These data indicate that
fatty acids may have a role in the regulation of Munc18c
expression, and are consistent with a previous study that
showed increased Munc18c protein levels in mice fed a
high-fat diet (25). Because the patients with type 2 diabetes
had higher levels of plasma triglycerides and skeletal muscle
lipid accumulation compared with healthy control subjects,
we thus propose that an increased inﬂow of lipids to the
skeletal muscle may partly explain the increased expression
of Munc18c in these patients.
These data may suggest that environmental inﬂuences
may be important in promoting Munc18c expression, but
they do not exclude a role for genetic inﬂuences that may,
for example, determine the extent of inﬂow of lipids to the
skeletal muscle cells. To further address this possibility,
we compared the expression of Munc18c in skeletal
muscle from the two sets of monozygotic twins discussed
above. We did not observe a signiﬁcant increase in
Munc18c expression in the twins with type 2 diabetes
compared with the nondiabetic cotwins, which argues for
a potential genetic inﬂuence on the increased expression
of Munc18c in patients with type 2 diabetes.
Overexpression and knockdown experiments indicated
that Munc18c may regulate the cellular levels of SNAP23
but not the cellular distribution of SNAP23. Thus, we
propose that the increased levels of Munc18c in the
skeletal muscle from patients with type 2 diabetes could at
least partially explain the increase in total SNAP23 levels
but not the redistribution to the microsomal/cytosolic
fraction. We also showed that SNAP23 did not form a
complex with Munc18c, which excludes a heterodimeriza-
tion between the two proteins as an explanation for the
role of Munc18c on SNAP23 expression.
In summary, the main ﬁnding from our present study
indicates that SNAP23 is redistributed to the cell interior in
skeletal muscle from patients with type 2 diabetes. Together
with our previous in vitro experiments, these results indicate
that the redistribution of SNAP23 could play an important
role in the development of insulin resistance/type 2 diabetes.
We also propose that Munc18c, which increased in patients
with type 2 diabetes, is a potential regulator of SNAP23
expression but not of its redistribution.
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